Drug Trial Radar · NCT01112306
ACT-293987 in Pulmonary Arterial Hypertension
Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
709
Actual
Start
Jul 7, 2010
Primary completion
Aug 26, 2021
Study completion Aug 26, 2021
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 28, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)
Conditions
- Pulmonary Arterial Hypertension
Interventions
ACT-293987Drug
Tablets, twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention DiscontinuationTime frame: Up to 3 days after study drug discontinuation (Up to 10.5 years)
- Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 3 Days After Study Intervention DiscontinuationTime frame: Up to 3 days after study drug discontinuation (Up to 10.5 years)
- Number of Participants With TEAEs Leading to Permanent Discontinuation of Study InterventionTime frame: Up to 10.5 years
Locations
157 sites in 38 countries. Site status is shown where the registry gives one.
Site not named
Mobile, Alabama
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
Sacramento, California
Site not named
Torrance, California
Site not named
Newark, Delaware
Site not named
Atlanta, Georgia
Site not named
Augusta, Georgia
Site not named
Austell, Georgia
Site not named
Carmel, Indiana
Site not named
Iowa City, Iowa
Site not named
Kansas City, Kansas
Site not named
Louisville, Kentucky
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Detroit, Michigan
Site not named
Troy, Michigan
Site not named
Rochester, Minnesota
Site not named
Chesterfield, Missouri
Site not named
St Louis, Missouri
Site not named
Newark, New Jersey
Site not named
Islandia, New York
Site not named
New York, New York
Site not named
The Bronx, New York
Site not named
Durham, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Cleveland, Ohio
Site not named
Columbus, Ohio
Site not named
Bend, Oregon
Site not named
Portland, Oregon
Site not named
Doylestown, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
York, Pennsylvania
Site not named
Nashville, Tennessee
Site not named
Dallas, Texas
Showing 40 of 157 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.